Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4809-4812

  Suzuki, Takayoshi ^a   Kouketsu, Akiyasu ^a   Itoh, Yukihiro ^a   Hisakawa, Shinya ^a   Maeda, Satoko ^b   Yoshida, Minoru ^b,c   Nakagawa, Hidehiko ^a   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC COMPOUND; ALPHA TUBULIN; CHAP 31; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 6 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE; IC 50; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; TUBULIN;

EID: 33746894565     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060554y     Document Type: Article

References (37)

1. (a) Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
2. (b) Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000, 19, 1176-1179.
3. (c) Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr, Opin. Genet. Dev. 1999, 9, 40-48.
4. (d) Hassig, C. A.; Schreiber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1997, 1, 300-308.
5. (a) Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes. Angew. Chem., Int. Ed. Engl. 2005, 44, 3186-3216.
6. (b) Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25, 261-309.
7. (c) Suzuki, T.; Miyata, N. Epigenetic control using natural products and synthetic molecules. Curr. Med. Chem. 2006, 13, 935-958.
8. (d) Schaefer, S.; Jung, M. Chromatin modifications as targets for new anticancer drugs. Arch. Pharm. 2005, 338, 347-357.
9. (a) Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280, 26729-26734.
10. (b) Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.; Yao, T. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417, 455-458.
11. (c) Matsuyama, A.; Yoshimatsu, Y.; Shimazu, T.; Sumida, Y.; Osada, H.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Horinouchi, S.; Yoshida, M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 21, 6820-6831.
12. (d) Kovacs, J. J.; Murphy, P. J.; Gaillard, S.; Zhao, X.; Wu, J. T.; Nicchitta, C. V.; Yoshida, M.; Toft, D. O.; Pratt, W. B.; Yao, T. P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18, 601-607.
13. Hideshima, T.; Bradner, J. E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S. L.; Anderson, K. C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8567-8572.
14. (a) Miller, T. A.; Witter, D. J.; Belvedere, S. Histone Deacetylase Inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
15. (b) Yoshida, M.; Matsuyama, A.; Komatsu, Y.; Nishino, N. From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. 2003, 10, 2351-2358.
16. (c) Miller, T. A. Patent status of histone deacetylase inhibitors. Expert Opin. Ther. Pat. 2004, 14, 791-804.
17. (d) Weinmann, H.; Ottow, E. Histone deacetylase inhibitors: a survey of recent patents. Expert Opin. Ther. Pat. 2005, 15, 1677-1690.
18. (a) Yoshida, M.; Kijima, M.; Akita, T.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
19. (b) Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 1995, 17, 423-430.
20. (a) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 93, 3003-3007.
21. (b) Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5705-5708.
22. Komatsu, Y.; Tomizaki, K. Y.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001, 61, 4459-4466.
23. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
24. Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives. J. Med. Chem. 1999, 42, 3001-3003.
25. (a) Suzuki, T.; Miyata, N. Non-hydroxamate histone deacetylase inhibitors. Curr. Med. Chem. 2005, 12, 2867-2880.
26. (b) Wong, J. C.; Hong, R.; Schreiber, S. L. Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. J. Am. Chem. Soc. 2003, 125, 5586-5587.
27. (c) Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92.
28. (d) Glaser, K. B.; Li, J.; Pease, L. J.; Staver, M. J.; Marcotte, P. A.; Guo, J.; Frey, R. R.; Garland, R. B.; Heyman, H. R.; Wada, C. K.; Vasudevan, A.; Michaelides, M. R.; Davidsen, S. K.; Curtin, M. L. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 2004, 325, 683-690.
29. (e) Suzuki, T.; Matsuura, A.; Kouketsu, A.; Hisakawa, S.; Nakagawa, H.; Miyata, N. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Bioorg. Med. Chem. 2005, 13, 4332-4342.
30. (a) Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. Chem. Biol. 2003, 10, 383-396.
31. (b) Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
32. (c) Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin. Org. Lett. 2001, 3, 4239-4242.
33. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3313-3317.
34. Suzuki, T.; Nagano, Y.; Kouketsu, A.; Matsuura, A.; Maruyama, S.; Kurotaki, M.; Nakagawa, H.; Miyata, N. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem. 2005, 48, 1019-1032.
35. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype Selective Substrates for Histone Deacetylases. J. Med. Chem. 2004, 47, 5235-5243.
36. Watanabe, L. A.; Jose, B.; Kato, T.; Nishino, N.; Yoshida, M. Synthesis of 1-α-amino-ω-bromoalkanoic acid for side chain modification. Tetrahedron Lett. 2004, 45, 491-494.
37. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. J. Med. Chem. 2005, 48, 3344-3353.